FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2400510618> ?p ?o ?g. }

• W2400510618 endingPage "194S" @default.
• W2400510618 startingPage "187S" @default.
• W2400510618 abstract "This study was designed to test the efficacy of 400 mg fleroxacin given orally as a single dose or once daily for 3 days against acute bacterial diarrhea. A group of 508 adults with acute diarrhea were entered into a randomized, double-blind, placebo-controlled, multicenter trial. Patients were examined and asked about numbers of liquid stools daily for 3 days and at 5 days after start of treatment. Repeat stool samples were obtained for culture on days 3 and 5 after start of treatment. A total of 332 patients showed stool cultures positive for bacterial pathogens sensitive to fleroxacin and completed their treatments. Patients treated with fleroxacin, both single-dose and 3-day regimens, showed faster clinical improvement than did placebo-treated patients, as shown by earlier cessation of diarrhea (p <0.001) and reductions in mean number of loose stools per day on days 2, 3, and 5 after start of therapy (p <0.05). Bacteriologic efficacy was demonstrated by negative stool cultures for initial pathogens on days 3 and 5 after start of therapy in 94% of patients treated with single doses of fleroxacin and in 93% of patients treated with three doses of fleroxacin as compared with 57% of patients treated with placebo (p <0.001). Patients with cholera, shigellosis, and infections due to Vibrio parahaemolyticus showed both clinical and bacteriologic responses to fleroxacin treatment, whereas patients with salmonellosis showed only bacteriologic responses. The good overall clinical and bacteriologic responses of most patients with acute bacterial diarrhea to fleroxacin indicate that this convenient single-dose therapy should be advantageous for empiric treatment of certain diarrheal illnesses. This study was designed to test the efficacy of 400 mg fleroxacin given orally as a single dose or once daily for 3 days against acute bacterial diarrhea. A group of 508 adults with acute diarrhea were entered into a randomized, double-blind, placebo-controlled, multicenter trial. Patients were examined and asked about numbers of liquid stools daily for 3 days and at 5 days after start of treatment. Repeat stool samples were obtained for culture on days 3 and 5 after start of treatment. A total of 332 patients showed stool cultures positive for bacterial pathogens sensitive to fleroxacin and completed their treatments. Patients treated with fleroxacin, both single-dose and 3-day regimens, showed faster clinical improvement than did placebo-treated patients, as shown by earlier cessation of diarrhea (p <0.001) and reductions in mean number of loose stools per day on days 2, 3, and 5 after start of therapy (p <0.05). Bacteriologic efficacy was demonstrated by negative stool cultures for initial pathogens on days 3 and 5 after start of therapy in 94% of patients treated with single doses of fleroxacin and in 93% of patients treated with three doses of fleroxacin as compared with 57% of patients treated with placebo (p <0.001). Patients with cholera, shigellosis, and infections due to Vibrio parahaemolyticus showed both clinical and bacteriologic responses to fleroxacin treatment, whereas patients with salmonellosis showed only bacteriologic responses. The good overall clinical and bacteriologic responses of most patients with acute bacterial diarrhea to fleroxacin indicate that this convenient single-dose therapy should be advantageous for empiric treatment of certain diarrheal illnesses." @default.
• W2400510618 created "2016-06-24" @default.
• W2400510618 creator A5000580748 @default.
• W2400510618 creator A5019419595 @default.
• W2400510618 creator A5026525839 @default.
• W2400510618 creator A5056701297 @default.
• W2400510618 creator A5060288877 @default.
• W2400510618 creator A5073499041 @default.
• W2400510618 creator A5076874522 @default.
• W2400510618 creator A5083539606 @default.
• W2400510618 date "1993-03-01" @default.
• W2400510618 modified "2023-09-25" @default.
• W2400510618 title "Treatment of Acute Bacterial Diarrhea: A Multicenter International Trial Comparing Placebo with Fleroxacin Given as a Single Dose or Once Daily for 3 Days" @default.
• W2400510618 cites W1545317975 @default.
• W2400510618 cites W1582972609 @default.
• W2400510618 cites W1845002279 @default.
• W2400510618 cites W1913707490 @default.
• W2400510618 cites W1962928558 @default.
• W2400510618 cites W1965912800 @default.
• W2400510618 cites W1979479099 @default.
• W2400510618 cites W1983786810 @default.
• W2400510618 cites W1983831701 @default.
• W2400510618 cites W2003755731 @default.
• W2400510618 cites W2006109029 @default.
• W2400510618 cites W2017738365 @default.
• W2400510618 cites W2020623845 @default.
• W2400510618 cites W2028403850 @default.
• W2400510618 cites W2034416669 @default.
• W2400510618 cites W2036058343 @default.
• W2400510618 cites W2066226792 @default.
• W2400510618 cites W2074863486 @default.
• W2400510618 cites W2086894988 @default.
• W2400510618 cites W2102701635 @default.
• W2400510618 cites W2105563801 @default.
• W2400510618 cites W2108063154 @default.
• W2400510618 cites W2110316115 @default.
• W2400510618 cites W2112746103 @default.
• W2400510618 cites W2116550336 @default.
• W2400510618 cites W2130259373 @default.
• W2400510618 cites W2155612020 @default.
• W2400510618 cites W2338441129 @default.
• W2400510618 cites W2415669767 @default.
• W2400510618 cites W2417053731 @default.
• W2400510618 doi "https://doi.org/10.1016/s0002-9343(20)31163-3" @default.
• W2400510618 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8452179" @default.
• W2400510618 hasPublicationYear "1993" @default.
• W2400510618 type Work @default.
• W2400510618 sameAs 2400510618 @default.
• W2400510618 citedByCount "17" @default.
• W2400510618 countsByYear W24005106182012 @default.
• W2400510618 countsByYear W24005106182014 @default.
• W2400510618 countsByYear W24005106182017 @default.
• W2400510618 countsByYear W24005106182018 @default.
• W2400510618 crossrefType "journal-article" @default.
• W2400510618 hasAuthorship W2400510618A5000580748 @default.
• W2400510618 hasAuthorship W2400510618A5019419595 @default.
• W2400510618 hasAuthorship W2400510618A5026525839 @default.
• W2400510618 hasAuthorship W2400510618A5056701297 @default.
• W2400510618 hasAuthorship W2400510618A5060288877 @default.
• W2400510618 hasAuthorship W2400510618A5073499041 @default.
• W2400510618 hasAuthorship W2400510618A5076874522 @default.
• W2400510618 hasAuthorship W2400510618A5083539606 @default.
• W2400510618 hasConcept C126322002 @default.
• W2400510618 hasConcept C141071460 @default.
• W2400510618 hasConcept C142724271 @default.
• W2400510618 hasConcept C204787440 @default.
• W2400510618 hasConcept C27081682 @default.
• W2400510618 hasConcept C2776986154 @default.
• W2400510618 hasConcept C2777316974 @default.
• W2400510618 hasConcept C2778049240 @default.
• W2400510618 hasConcept C2778512257 @default.
• W2400510618 hasConcept C2779546430 @default.
• W2400510618 hasConcept C2779802037 @default.
• W2400510618 hasConcept C2781065037 @default.
• W2400510618 hasConcept C501593827 @default.
• W2400510618 hasConcept C523546767 @default.
• W2400510618 hasConcept C54355233 @default.
• W2400510618 hasConcept C71924100 @default.
• W2400510618 hasConcept C86803240 @default.
• W2400510618 hasConcept C89423630 @default.
• W2400510618 hasConcept C90924648 @default.
• W2400510618 hasConceptScore W2400510618C126322002 @default.
• W2400510618 hasConceptScore W2400510618C141071460 @default.
• W2400510618 hasConceptScore W2400510618C142724271 @default.
• W2400510618 hasConceptScore W2400510618C204787440 @default.
• W2400510618 hasConceptScore W2400510618C27081682 @default.
• W2400510618 hasConceptScore W2400510618C2776986154 @default.
• W2400510618 hasConceptScore W2400510618C2777316974 @default.
• W2400510618 hasConceptScore W2400510618C2778049240 @default.
• W2400510618 hasConceptScore W2400510618C2778512257 @default.
• W2400510618 hasConceptScore W2400510618C2779546430 @default.
• W2400510618 hasConceptScore W2400510618C2779802037 @default.
• W2400510618 hasConceptScore W2400510618C2781065037 @default.
• W2400510618 hasConceptScore W2400510618C501593827 @default.
• W2400510618 hasConceptScore W2400510618C523546767 @default.
• W2400510618 hasConceptScore W2400510618C54355233 @default.
• W2400510618 hasConceptScore W2400510618C71924100 @default.
• W2400510618 hasConceptScore W2400510618C86803240 @default.

• next